Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cell Signal. Author manuscript; available in PMC 2012 September 1.
Published in final edited form as:
PMCID: PMC3115457

Identification of new Gβγ interaction sites in adenylyl cyclase 2


The role of Gβγ in adenylyl cyclase (AC) signaling is complicated due to its role as a conditional activator (AC2, AC4 and AC7) and an inhibitor (AC1, AC3 and AC8). AC2 is stimulated by Gαs and if Gβγ is present the stimulation is synergistic. The precise mechanism of this synergistic activation is still not known. In order to further elucidate the role of Gβγ in AC2 activation by Gαs, peptides derived from the C1 domains of AC2 were synthesized and the ability of the various peptides to regulate AC2 function was tested. Our results identify two new Gβγ-binding sites in the AC2 C1 domain, AC2 C1a 339-360 and AC2 C1b 578-602 that are involved with stimulation of AC2 by Gβγ. These two regions are different from the previously described QEHA motif in the C2 domain of AC2. Further, the recently discovered PFAHL motif was confirmed to bind and to be involved with stimulation of AC2 by Gβγ. These functional studies indicate that multiple regions of AC2 are involved in the interaction with Gβγ.

Keywords: adenylyl cyclase, cyclic AMP, G-protein, Gβγ, Gαs, peptide

1. Introduction

The adenylyl cyclases (AC 1-9) are the membrane-bound enzymes responsible for the generation of cAMP [1, 2]. The cAMP pathway orchestrates the signal transduction initiated by many hormones, neurotransmitters, and autocrine and paracrine factors to regulate a diversity of cellular functions [3]. Although the cAMP pathway is ubiquitous, both the receptors that couple to it and the various isoforms of the membrane-bound adenylyl cyclases that produce cAMP, are expressed in a tissue-selective manner [1]. Adenylyl cyclases are activated by stimulation of a variety of receptors coupled through the alpha unit (Gαs) of the heterotrimeric guanine nucleotide binding protein, Gs. The various AC isoforms are also regulated by other molecules, such as calcium, calcium-calmodulin, calcium-calcineurin, cAMP dependent kinase, other G protein α-subunits (Gαi, Gαo and Gαz) and Gβγ [4, 5]. Whether the regulatory interaction is stimulatory or inhibitory depends on the isoform of AC and the identity of the regulatory molecule. Gβγ activates AC2, AC4, and AC7 [6-12] in the presence of Gαs or forskolin but inhibits AC1, AC3 and AC8 [12-15]. Gβγ interacts with AC5 and AC6 but whether the interaction is inhibitory or stimulatory is currently not clear [16, 17].

The interaction underlying the synergistic activation of AC2 by Gβγ in the presence of Gαs is the focus of this study. The AC2 site responsible for activation by Gβγ was tentatively assigned to the C-terminal half of the molecule [8]. Subsequently, a Gβγ-binding element, QEHA (QEHAQEPERQYMHIGTMVEFAYALVGK) on the C2a domain of AC2 was identified [9, 18]. Recently, it was discovered that while the QEHA motif in the C2a domain of AC2 was important for interaction with Gβγ, a region coined the PFAHL motif (MTRYLESWGAAKPFAHL), in the C1b domain of AC2 was found to be essential for stimulation by Gβγ [15, 19]. Another recent study defined a region in the AC2 C2a domain, coined the KF-loop (LSKPKFSGV), as an essential motif for stimulation of Gαs activation AC2 by Gβγ [20]. Currently, it is not clear if these are the only regions involved in the interaction with AC2 or if other regions are involved.

In the present study, peptides derived from the C1a and C1b domains of AC2 were synthesized and the ability of the various peptides to bind to Gβγ and to inhibit AC2 activation by Gβγ was tested. Our results identify two new Gβγ-binding sites in the AC2 C1b domain. A peptide containing the sequence of the previously described [15] PFAHL motif was also confirmed to bind Gβγ and inhibit the stimulation of AC2 by Gβγ.

2. Materials and Methods

2.1 Peptide synthesis

Peptides were either synthesized in-house or purchased from Celtek Peptides, Inc. (Nashville, TN). In-house synthesized peptides followed the Fmoc protocol on Wang resin. Fmoc-protected amino acids, Wang resin and HBTU (O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate) were purchased from Protein Technologies (Louisville, KY). The peptides were synthesized on a Symphony (Protein Technologies, Tucson, AZ) peptide synthesizer using the Fmoc protocol on Wang resin. Briefly, the resin was equilibrated in DMF (Fisher Scientific). Fmoc deprotection was achieved using piperidine (Sigma-Aldrich, St. Louis, MO) in N-methylmorpholine (NMP; Fisher Scientific). Coupling reactions were performed with 5-fold excess amino acid with respect to resin loading, in NMP with HBTU as a coupling reagent. The deprotection mixture consisted of trifluoroacetic acid (TFA), phenol, ethanedithiol, thioanisol and H2O (ratio of 10:0.75:0.25:0.50:0.50; all from Sigma-Aldrich). Peptides were extracted with ether and dried under nitrogen. The purity of the peptides was assessed by HPLC on a C18 reversed phase (RP) column (Grace-Vydac, Columbia, MD) with solvent A as 0.1% TFA in H2O and solvent B as 0.1% TFA in acetonitrile and on a gradient of 0.5% B per min. If peptides were less than 80% pure, purification was performed using a semi-preparative C18 RP column. Masses were verified by MALDI-TOF (Voyager-DE PRO MALDI-TOF, Applied Biosystems, Foster City, CA) at the Mass Spectrometry Core Facility, Weill Medical College of Cornell University in New York, NY.

2.2 Biacore surface plasmon resonance binding assays

All experiments were performed on a Biacore 2000 instrument. Biotinylated peptides were immobilized on a streptavidin Biacore chip. A solution of Gβγ in 25 mM HEPES (pH 8.0) was flowed over each chip at concentrations of 12.5, 25, 50, 100 and 200 nM, at a flow rate of 20 μL/min. The data were fitted using the Biacore Biaevaluation software (Version 3.1) to determine the KD value for each peptide. The residue plots represent the efficiency of data-fitting at each timepoint in the binding isotherm.

2.3 Adenylyl cyclase activity assays

Two assay types were used to assess AC2 activity in membrane preparations from Hi5 cells infected with recombinant AC2 baculovirus. The membrane preparation was described previously [21]. The constitutively active form of Gαs (Q227L) was synthesized as described by Harry et al. [22]. Gβγ was isolated from Hi5 cells using the protocol previously described protocol [23]. Baculovirus constructs for Gβ1 and His-tagged Gγ2 were kindly provided by Jim Garrison (Department of Pharmacology, University of Virginia).

The radioactive activity assay for detection of [α-32P]ATP conversion to [32P]cAMP has been described [22, 24]. Briefly, the peptides were mixed with adenylyl cyclase-expressing membranes and held on ice for 10 min prior to assays. AC2-membranes were added to assay tubes such that the final amount of membrane protein per tube was 1–2 μg. The concentration of activated Gαs was 2 nM and that of Gβγ was 200 nM. The ability of the peptide to inhibit Gαs activation of AC2 and basal AC2 activity was also tested.

The non-radioactive cAMP assay kit (Lance cAMP assay) was purchased from Perkin Elmer Life and Analytical Sciences (Wellesley, MA). The manufacturer’s protocol was followed with the exception of using a membrane preparation (1 μg of AC2 membrane protein per well) in place of cells. The stimulation buffer contained 20 mM Hepes pH 8.0, 2 mM DTT, 1 mM EDTA, 11 mM MgCl2, 100 μM ATP with regeneration system (myokinase, creatine phosphokinase and creatine phosphate) and a mixture of protease inhibitors (0.5 mM IBMX, 3.2 μg/ml leupeptin, 1 μg/ml aprotinin, 1 mM phenanthroline, and 1 mM phenylmethylsulfonyl fluoride). The peptides were dissolved in stimulation buffer at 4 times the assay concentration. Next, 5 μL of the peptide solutions were pipetted to the assay plate (Costar, 96-well half-area, white-walled) followed by 5 μL Gαs and Gβγ at double the assay concentration. The solution of peptide with G proteins was incubated for 30 minutes at room temperature. Next, 10 μL of the AC2 membranes (2 μg membrane protein per well) in stimulation buffer was added and the stimulation reaction was incubated for 15 minutes at room temperature. The final concentrations of Gαs and Gβγ were 20 nM and 1 μM, respectively. Controls for basal cAMP level, Gαs-stimulation alone and Gαs+ Gβγ-stimulation without peptide are run alongside peptide samples. Samples were read using a Wallac Envision 2101 Multilabel Reader with Wallac Envision Manager software and the manufacturer’s recommended settings. A standard curved was generated using a standardized cAMP solution diluted in stimulation buffer and the Lance fluorescence values are converted to cAMP concentrations by interpolating the values using a non-linear regression in GraphPad Prism Version 5.

All experiments were repeated two or more times with qualitatively similar results. Typical experiments are shown. Values are means of duplicate determinations and coefficients of variance were < 7%.

3. Results

3.1 Peptide design and synthesis

Several peptides with sequences of regions the C1 domain of AC2 were synthesized (Figure 1). The sequences were designed to cover regions the C1b domain almost in its entirety and a region from the C1a domain that displays high homology, specifically higher amongst the adenylyl cyclase isoforms stimulated by Gβγ (Figure 7A) than in the AC isoforms that are stimulated by Gβγ (AC2, AC4, AC5, AC6 and AC7). The relative location of the peptides in the AC2 sequence is depicted by color-coding in the AC2 structural schematic (Figure 1A) and their sequences are displayed (Figure 1B). We originally synthesized the AC2 C1b 495-514 peptide (RYLESWGAAKPFAHLHHRDS) that differed by several residues from the published PFAHL region analyzed by Diel et al. (493-509, MTRYLESWGAAKPFAHL) [15]. For direct comparison, we synthesized the PFAHL region peptide (AC2 C1b 493-509) used by Diel et al. [15]. We also synthesized a peptide from the region adjacent to the PFAHL sequence, AC2 C1b 514-541. Data for the previously published QEHA region (AC2 C2 956-982) is shown for comparison.

Figure 1
AC2 peptide design
Figure 7
Homology of regions within the C1 and C2 domains of AC isoforms and structural analysis of AC activation

3.2 Several novel regions of AC2 display a binding interaction with Gβγ

Biacore surface plasmon resonance (SPR) was used to determine the binding affinity of the peptides for Gβγ by flowing varying concentrations of Gβγ over the biotin-immobilized peptide surface. Several peptides with sequences within the AC2 C1a, C1b and C2 regions displayed high affinities for Gβγ (Table 1). The QEHA region peptide (C2 956-982), previously reported to interact with Gβγ [25], displayed a KD of 13.9 ± 8.8 nM (Figure 4D, Table 1). A new, C1a region (339-360, CYYCVSGLPISLPNHAKNCVKM), was found to bind Gβγ (KD 40.5 ± 6.3 nM, Figure 2A, Table 1). Peptides which encode the C1b region in entirety were tested and the PFAHL region peptides and a novel region (578-602, ISLLFYNKVLEKEYRATALPAFKYY) were found to have a high affinity interaction with Gβγ (Table 1). AC2 C1b 578-602 had a KD of 102 ± 14 nM (Figure 4B). The PFAHL peptides had similar affinities AC2 C1b 493-509 (KD 2.7 ± 1.3 nM, Figure 3A) and 495-514 (KD 2.7 ± 1.3 nM, Figure 3B). The other C1b peptides tested, 515-541 (MTTENGKISTTDVPMGQHNFQNRTLR) and 554-577 (ERMIQAIDGINAQKQWLKSEDIQR) displayed minimal affinity (KD >10 μM) (Figure (Figure3C3C and and4A).4A). To rule out non-specific binding, several amino acids were changed to alanines and charged amino acids were changed to oppositely charged amino acids in the C1a and one C1b high affinity peptides (AC2 C1a 339-360 scrm and AC2 C1b 578-602 scrm, Figure 1B). The scrambled forms of the C1a 339-360 and C1b 578-602 peptides did not display affinity for Gβγ (Table 1 and Figure 2B and Figure 4C, respectively).

Figure 2
Biacore binding isotherms for interaction between Gβγ and immobilized AC2 C1a peptides and Gβγ
Figure 3
Biacore binding isotherms for interaction between Gβγ and immobilized AC2 C1b PFAHL region peptides
Figure 4
Biacore binding isotherms for interaction between Gβγ and immobilized AC2 C1b and C2 peptides
Table 1
Binding constants (KD) calculated from Biacore plots for the binding of Gβγ to immobilized AC2 peptides. Concentrations of 12.5, 25, 50, 100 and 200 nM of Gβγ were tested for each peptide. The data were fitted with the ...

3.3 Several new regions of AC2 mediate synergistic stimulation by Gαs and Gβγ

The ability of the various peptides to reduce the stimulation of AC2 by Gβγ and Gαs was assayed. Gαs increases the activity of AC2 by approximately 2- to 5-fold over basal and Gβγ further increases Gαs – stimulated AC2 activity another 3- to 6-fold (15- to 30-fold over basal, Figures Figures55 and and6).6). The C1a (339-360), C1b (578-602), C1b (495-514) and C1b (493-509) peptides inhibited Gαs/Gβγ stimulation of AC2. The 578-602 C1b peptide inhibited Gβγ stimulation of Gαs-activated AC2 completely, bringing the cAMP level below that of Gαs stimulation (Figure 5A) with an IC50 of 578-602 of 2.2 μM (Table 2). The C1a (339-360) exhibited a strong inhibition of Gβγ stimulation of Gαs-activated AC2 (Figure 5A), with an inhibition of 88.0% at the highest concentration tested (300 μM) and IC50 of 5.6 μM peptide (Table 2). The PFAHL C1b (493-509 and 495-514) peptides exhibited inhibition of Gβγ synergistic stimulation of AC2 (Figure (Figure5A5A and and6A)6A) with the 495-514 peptide displaying 67.0% maximal inhibition with an IC50 value of 13.9 μM (Table 2). The C1b peptides that did not display binding to Gβγ in the Biacore SPR assay (C1b 515-541, 554-577), also did not display any inhibitory effect in Gβγ activation of AC2. With the exception of the 578-602 C1b peptide, all of peptides exhibited a partial inhibition on Gαs activity alone at higher concentrations of peptide (Figure (Figure5B5B and and6B).6B). The maximal inhibitions of Gαs active ranged from 15.3 to 39.1% and the IC50 values ranged from 36.7 to 82.3 μM (Table 2). The 578-602 C1b peptide, exhibited a more pronounced effect (Figure (Figure5B5B and and6B).6B). The maximal inhibition by the 578-602 C1b peptide on Gαs activity was 50.6%, with an IC50 value of 2.5 μM (Table 2). All of the peptides caused a small reduction of basal activity (maximal 14.1 to 36.7%) with IC50 values ranging from 7.7 to >100 μM (Table 2 and Figures Figures5C5C and and6C6C).

Figure 5
Modulation of AC2 activation by Gβγ by various AC2 peptides
Figure 6
Modulation of AC2 activation by Gβγ by AC2 PFAHL C1b peptides
Table 2
Percent maximal inhibition values and IC50 values for the activity of each listed peptide to inhibit basal or Gαs stimulation of AC2 or Gβγ stimulation of Gαs-stimulated AC2. Peptides were tested at a concentration range ...

4. Discussion

Depending on the identity of adenylyl cyclase isoform, Gβγ either activates or inhibits the enzyme. Specifically, AC2, AC4, and AC7 [6-12] are activated by Gβγ in the presence of Gαs or forskolin and AC1, AC3 and AC8 [12-15] are inhibited by Gβγ. AC5 and AC6 interact with Gβγ but whether the interaction is inhibitory or stimulatory is yet to be determined [16, 17]. There is prominent homology (77-90%) between AC2, AC4 and AC7 in the C1b AC2 region, which also markedly changes amongst the AC isoforms that are inhibited by Gβγ (AC1, AC3, AC5, AC6 and AC8) (Figure 7B). There is also homology within a section of the C1a region of AC2 (Figure 7A). Therefore, a series of peptides representing the highly homologous AC2 C1b and AC2 C1a regions and a previously identified AC2 C2 region were synthesized and assayed (Figure 1). Binding between immobilized AC2 peptides and Gβγ was tested using Biacore SPR. The ability of the AC2 peptides to inhibit Gβγ-mediated synergistic activation of Gαs-induced AC2 activity was assayed.

The Gβγ-interaction of the previously identified AC2 C2 QEHA peptide was confirmed using Biacore SPR, along with the Gβγ-interaction of the AC2 C1b PFAHL region (Figures (Figures4D,4D, 3A and 3B and Table 1). Two AC2 peptides bound to Gβγ with affinities in the nanomolar range, representing two new interactions of Gβγ within the C1a region (AC2 C1a 339-360) and C1b region of AC2 (AC2 C1b 578-602; Figures Figures2A2A and and4B4B and Table 1). Two other C1b region peptides did not interact with Gβγ (AC2 C1b 515–541 and 554-577; Figures Figures3C3C and and4A4A and Table 1). Control, scrambled peptides (AC2 C1a 339-360 scrm and AC2 C1b 578-602 scrm) did not interact with Gβγ, indicating that the detected binding was specific (Figures (Figures2B2B and and4C4C and Table 1).

Two new regions of AC2 which interacted with Gβγ by Biacore SPR were shown to be involved with the activation of Gαs-stimulated AC2 by Gβγ using an enzymatic activity assay. The C1a 339-360 peptide domain almost completely inhibited Gαs/Gβγ-mediated AC activation (Figure 5A and Table 2), with minimal effect on Gαs-mediated activity alone (Figure 5B and Table 2). The AC2 C1b 578-602 peptide most strongly inhibited Gαs/Gβγ-mediated AC2 activation (Figure 5A and Table 2), but also partially inhibited Gαs-mediated activation of AC2. As shown previously by Diel et al. [15], the PFAHL peptides, AC2 C1b inhibited activation of AC2 by Gβγ in the presence of Gαs (Figures (Figures5A5A and and6A6A and Table 2). The two C1b peptides from the AC2 C1b region which lacked homology, AC2 515-541 and 554-577, did not have an effect on the synergistic Gαs/Gβγ-stimulation of AC2 (Figure 5A and Table 2). The C1b peptide 542-553 was not assayed due to synthesis difficulties.

Our Biacore findings indicate that the binding affinities of the interacting peptides from AC2 have increasing affinity for Gβγ in the following order: C1b 578-602 (102 nM), C1a 339-360 (40.5 nM), QEHA (13.9 nM), and C1b PFAHL or 495-514 (2.7 to 4.7 nM). The abilities to block Gαs/Gβγ-mediated activation of AC2 of the interacting peptides increase as follows, according to their maximal inhibition of AC2: C1b PFAHL 495-514 (67.0%), C1a 339-360 (88.0%) and C1b 578-602 (>100%). The trends of the binding and activity differ, but the inhibition of Gαs–activity alone must be taken into account. The C1b 578-602 peptide bound with the weakest affinity and showed the strongest inhibition of Gβγ/Gαs activity, but also inhibited Gαs activity alone the most strongly, by 50.6%. The relatively low affinity of and relatively strong inhibition of Gαs activity by the C1b 578-602 peptide supports the possibility that this C1b sequence spans the two regions of AC2 that interact with Gβγ and Gαs. Alternatively, this peptide may cause a rearrangement of AC2 which allosterically affects Gαs-mediated AC2 activity. The PFAHL peptide(s) bound to Gβγ with the highest affinity and showed the weakest relative inhibition of Gβγ/Gαs activity, but this peptide had a minimal effect on Gαs activity alone, indicating that this region of AC2 mediates the Gβγ interaction alone. The C1a region has an affinity of 40 nM, in the middle trend of the AC2 interacting regions, and this peptide inhibited Gβγ/Gαs activity by 88% with 36.1% inhibition of Gαs activity alone only at higher concentrations (IC50 of 82.3 μM). This result supports the possibility that this novel C1a region also interacts with Gβγ alone.

The binding and activity data are supported by the homology across the AC isoforms in each region. The strong homology between AC2, AC4, and AC7 in the C1a 339-360 region (85%) and PFAHL region (80-89%) corroborates that these regions are functionally important for the interaction of Gβγ with the AC isoforms that are Gβγ -stimulated (Figure 7A and 7B). The homology in this region is present in the C1a region of the AC isoforms that are inhibited by Gβγ (AC1, AC3, AC5, AC6 and AC8), albeit to a lesser extent (51-65%), indicating that this region may play a role in the inhibitory Gβγ mechanism as well (Figure 7A). The homology in the PFAHL region markedly decreases (10-26%) amongst the AC isoforms that are inhibited by Gβγ (AC1, AC3, AC5, AC6 and AC8) (Figure 7B), indicating that this region most likely does not play a role in the inhibitory Gβγ mechanism. There is strong homology (60%) between AC2 and AC4 in the 578-602 C1b AC2 region (Figure 7B), which is reduced to 32% in AC7. The reduction in homology indicates that the mechanism of Gβγ-activation of the AC2 and AC7 may differ slightly with respect to this region being less important for AC7 activation. The homology in the 578-602 region markedly decreases amongst most AC isoforms that are inhibited by Gβγ (28-32% homology for AC5, AC6 and AC8 and 12% homology for AC1 and AC3, Figure 7B). The C1b region from 515-577 displays negligible homology across all the AC isoforms and the peptides from these regions did not display binding or strong inhibition of AC2 activity.

Structural [27] and activity data [24, 28] support that the C1 and C2 domains of AC are brought together by Gαs to allosterically activate the enzyme. The available AC structure was determined using AC5 C1 (residues 364-580) and ACII C2 (residues 874-1081) and only partially encompasses the cytosolic domains [27]. The AC constructs have a relatively low affinity for one another and minimal activity; however, in the presence of Gαs a high-affinity, active (≥ 150 μmol/min/mg) complex is formed [28], supporting the notion that Gαs brings the two domains together in an active formation. We propose that during this structural reorganization, the Gβγ-binding face on AC2 becomes exposed. Including the data reported herein, there are now five reported areas within AC2 that interact with Gβγ: one within the C1a region (339-360, reported here), two within the C1b region (PFAHL reported previously [15] and here and 578-602 reported here) and two within the C2 region (KF loop 925-933 reported previously [20] and QEHA reported by us and others [9, 18, 19, 29] and confirmed here). Taken together, these data support that Gβγ binds to several areas both the C1 and C2 regions of AC and that Gβγ allosterically rearranges the domains to a position that further favors enzymatic activity.

The structure of AC in complex with Gαs [27, 30] is displayed in Figure 7C, with AC5 C1 shown in green and AC2 C2 shown in red and Gαs is shown in blue. The structure of the AC C1b domain has not been solved and is represented by a dashed circle at the C-terminal region of the C1a domain in Figure 7C. Of the regions that are present in the structure, the Gαs-interaction regions within AC are non-overlapping with the Gβγ-interaction regions. The regions of AC2 that interact with Gαs include AC2 C2 α2′ region (904-921), AC2 C2 α3′ region (986-992) and the AC5 C1 N-terminal loop region (378-379). The AC2 α3′ region (986-992) region is proximal to but not overlapping with the QEHA region (956-982, highlighted in cyan in Figure 7C). The KF loop (927-933, highlighted in purple in Figure 7C) is proximal to the QEHA region and non-overlapping with Gαs-interaction regions. The C1a region (339-360, highlighted in orange in Figure 7C) is exposed in the Gαs-AC structure and includes a flexible loop region that most likely forms contacts with Gβγ. The C1b regions (PFAHL 493-514 and 578-602) were not included in the AC construct used for crystallization [27]. However, since the included Gβγ-interaction regions are arranged on one face of AC2 which is proximal to the C-terminal of the C1a domain, it is likely that the C1b domain extends in such a way that the Gβγ-binding regions within C1b are accessible to Gβγ (Figure 7C).

In previous studies, we have shown that the Switch I and II regions of Gαs are important for stimulation of AC2 [24]. Due to the construct of AC crystallized for the structure, the Switch I-AC interaction is omitted. The Switch I and II regions of Gαs are also involved in interactions between Gαs and Gβγ [22]. Thus the areas of Gαs which have affinity for Gβγ are occluded when Gαs is bound to AC2. This supports the notion that Gαs initially binds to AC2, structurally rearranging AC2 to expose the Gβγ-binding face, which is mutually exclusive from the Gαs binding face.

In conclusion, we have identified two novel regions of AC2 which play a role in the synergistic activation by Gβγ of Gαs-stimulated AC2. Our data support that Gβγ binds to the C1b face of AC2 that is exposed upon Gαs binding and that Gβγ binding to AC2 further rearranges the AC2 active site in order to increase the rate of substrate turnover. In order to definitively establish that the rearrangement of AC2 by Gαs-binding exposes a Gβγ-binding surface, it is necessary to obtain structural data to allow for comparison of the bound and unbound structures. Currently no structural data of full-length, membrane-bound adenylyl cyclases are available. Even with the full structural data for AC2, the activation process is complex and there are most likely to be differences across AC isoforms. Thus, the definitive understanding of how Gαs and Gβγ activate adenylyl cyclase awaits advances in crystal structures of membrane bound proteins. Recent data have shown that different isoforms of AC play different roles in opiate induced AC superactivation or superinhibition and that Gβγ plays a critical role in this signal regulation [31-33]. Also, current data suggests a role for Gβγ dimers in these processes [34]. The mechanistic information revealed by this study contributes to the overall understanding of the complex signaling involved with adenylyl cyclases and Gβγ.


This research is supported by NIH grant CK-38761 and GM54508.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


[1] Iyengar R. FASEB J. 1993;7:768–755. [PubMed]
[2] Taussig R, Gilman AG. 1995;270:1–4. [PubMed]
[3] Ross EM, Gilman AG. Annu. Rev. Biochem. 1980;49(533-564) [PubMed]
[4] Tang WJ, Yan S, Drum CL. Adv. Second Messenger Phosphoprotein Res. 1998;32:137–151. [PubMed]
[5] Pieroni J, Jacobowitz O, Chen J, Iyengar R. Curr. Opin. Neurobiol. 1993;3:345–351. [PubMed]
[6] Gao X, Sadana R, Dessauer CW, Patel TB. J. Biol. Chem. 2007;282(1):294–308. [PubMed]
[7] Steiner D, Saya D, Schallmach E, Simonds WF, Vogel Z. Cell. Signal. 2006;18(1):62–68. [PubMed]
[8] Tang WJ, Gilman AG. Science. 1991;254(5037):1500–1503. [PubMed]
[9] Chen J, DeVivo M, Dingus J, Harry A, Li J, Sui J, Carty DJ, Blank JL, Exton JH, Stoffel RH, Inglese J, Lefkowitz RJ, Logothetis DE, Hildebrandt JD, lyengar R. Science. 1995;268(5214):1166–1169. [PubMed]
[10] Gao BN, Gilman AG. Proc. Natl. Acad. Sci. USA. 1991;88(22):10178–10182. [PubMed]
[11] Yoshimura M, Ikeda H, Tabakoff B. Mol Pharmacol. 1996;50(4):43–51. [PubMed]
[12] Choi E-J, Xia Z, Villacres EC, Storm DR. Curr. Opin. Cell Biol. 1993;5(2):269–273. [PubMed]
[13] Taussig R, Quarmby LM, Gilman AG. J Biol Chem. 1993;268(1):9–12. [PubMed]
[14] Tang W-J, Krupinski J, Gilman AG. J Biol Chem. 1991;266(13):8595–8603. [PubMed]
[15] Diel S, Klass K, Wittig B, Kleuss C. J. Biol. Chem. 2006;281(1):288–294. [PubMed]
[16] Gao X, Sadana R, Dessauer CW, Patel TB. J Biol Chem. 2007;282(1):294–302. [PubMed]
[17] Bayewitch ML, Avidor-Reiss T, Levy R, Pfeuffer T, Nevo I, Simonds WF, Vogel Z. FASEB J. 1998;12(11):1019–1025. [PubMed]
[18] Weng G, Li J, Dingus J, Hildebrandt JD, Weinstein H, Iyengar R. J Biol Chem. 1996;271:26445–26448. [PubMed]
[19] Weitmann S, Schultz G, Kleuss C. Biochemistry. 2001;40(36):10853–10858. [PubMed]
[20] Diel S, Beyermann M, Llorens JM, Wittig B, Kleuss C. Biochem J. 2008;411(2):449–456. [PubMed]
[21] Pieroni JP, Harry A, Chen J, Jacobowitz O, Magnusson RP, Iyengar R. J. Biol. Chem. 1995;270(36):21368–21373. [PubMed]
[22] Harry A, Chen Y, Magnusson R, Iyengar R, Weng G. J. Biol. Chem. 1997;272(30):19017–19021. [PubMed]
[23] Davis TL, Bonacci TM, Sprang SR, Smrcka AV. Biochemistry. 2005;44(31):10593–10604. [PubMed]
[24] Chen Y, Yoo B, Lee JB, Weng G, Iyengar R. J. Biol. Chem. 2001;276:45751–45754. [PubMed]
[25] Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar R. Proc. Natl. Acad. Sci. USA. 1998;94:2648–2652. [PubMed]
[26] Chen J, DeVivo M, Dingus J, Harry A, Li J, Sui J, Carty DJ, Blank JL, Exton JH, Stoffel RH, et al. Science. 1995;268(5214):1166–1169. [PubMed]
[27] Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Science. 1997;278(5345):1907–1916. [PubMed]
[28] Sunahara RK, Dessauer CW, Whisnant RE, Kleuss C, Gilman AG. J Biol Chem. 1997;272(35):22265–22271. [PubMed]
[29] Chen Y, Weng G, Li J, Harry A, Pieroni J, Dingus J, Hildebrandt JD, Guarnieri F, Weinstein H, Iyengar R. Proc Natl Acad Sci U S A. 1997;94(6):2711–2714. [PubMed]
[30] Tesmer JJ, Sunahara RK, Johnson RA, Gosselin G, Gilman AG, Sprang SR. Science. 1999;285(5428):756–760. [PubMed]
[31] Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. J Biol Chem. 1996;271(35):21309–21315. [PubMed]
[32] Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. J Biol Chem. 1997;272(8):5040–5047. [PubMed]
[33] Schallmach E, Steiner D, Vogel Z. Neuropharmacology. 2006;20(8):998–1005. [PubMed]
[34] Steiner D, Avidor-Reiss T, Schallmach E, Saya D, Vogel Z. J Mol Neurosci. 2005;27(2):192–203.
[35] Pymol by DeLano Scientific LLC